escitalopram lundbeck 20 mg munsönderfallande tablett
h. lundbeck a/s - escitalopram - munsönderfallande tablett - 20 mg - escitalopram 20 mg aktiv substans; mannitol hjälpämne - escitalopram
quetiapine intas 200 mg depottablett
intas pharmaceuticals limited - kvetiapinfumarat - depottablett - 200 mg - laktosmonohydrat hjälpämne; kvetiapinfumarat 230,3 mg aktiv substans - kvetiapin
quetiapine intas 300 mg depottablett
intas pharmaceuticals limited - kvetiapinfumarat - depottablett - 300 mg - kvetiapinfumarat 345,45 mg aktiv substans; laktosmonohydrat hjälpämne - kvetiapin
quetiapine intas 400 mg depottablett
intas pharmaceuticals limited - kvetiapinfumarat - depottablett - 400 mg - laktosmonohydrat hjälpämne; kvetiapinfumarat 460,6 mg aktiv substans - kvetiapin
quetiapine intas 50 mg depottablett
intas pharmaceuticals limited - kvetiapinfumarat - depottablett - 50 mg - kvetiapinfumarat 57,575 mg aktiv substans; laktosmonohydrat hjälpämne - kvetiapin
ibandronatsyra liconsa 150 mg filmdragerad tablett
laboratorios liconsa s.a. - ibandronatnatriummonohydrat - filmdragerad tablett - 150 mg - ibandronatnatriummonohydrat 168,75 mg aktiv substans; laktosmonohydrat hjälpämne - ibandronat
calcichew-d3 citron 1000 mg/800 ie tuggtablett
orifarm healthcare a/s - kalciumkarbonat; kolekalciferol - tuggtablett - 1000 mg/800 ie - kalciumkarbonat 2500 mg aktiv substans; sackaros hjälpämne; kolekalciferol 20 mikrog aktiv substans; xylitol hjälpämne; isomalt hjälpämne - kombinationer med vitamin d och/eller övriga läkemedel
venlafaxin 1a farma 300 mg depottablett
1a farma a/s - venlafaxinhydroklorid - depottablett - 300 mg - venlafaxinhydroklorid 339,4 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
rapydan 70 mg/70 mg medicinskt plåster
eurocept international b.v. - lidokain; tetrakain - medicinskt plåster - 70 mg/70 mg - lidokain 70 mg aktiv substans; borax hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; tetrakain 70 mg aktiv substans - kombinationer
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.